We here show that cytotoxic human T cells engaged by extremely low amounts of an EpCAM/CD3-bispecific antibody construct, which is currently in a phase I trial, have the potential to completely eradicate two kinds of highly tumorigenic colorectal tumor-initiating cells. The gene discussed is EPCAM; the disease is colorectal neoplasm.